Novo Nordisk Stock Tumbles After Disappointing Weight Loss Trial

Novo Nordisk shares plummeted after analysts at Nordea and Deutsche Bank downgraded the company following disappointing trial results for the weight-loss drug CagriSema.Investors expressed concern over the firm's heavy reliance on obesity and diabetes markets as competition from Eli Lilly intensifies.Lars Fruergaard Jørgensen rejected claims the drug is obsolete while internal reports suggest the development pipeline is shifting toward riskier early-stage projects.